PA
EWTX icon

Perceptive Advisors’s Edgewise Therapeutics EWTX Stock Holding History

Perceptive Advisors’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-500,000
Closed -$11M – 94
2025
Q1 		$11M Buy
+500,000
New +$13.1M 0.39% 49

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Perceptive Advisors's EWTX Position: Q2 2026 in Review

Perceptive Advisors reduced its Edgewise Therapeutics (EWTX) stake by 1.1% in Q2 2026, selling an estimated $1.72M and leaving 4,373,974 shares worth $178M. The position accounts for 2.67% of the portfolio, ranked #11.

Perceptive Advisors first reported a position in EWTX in Q4 2023 and has held it in 11 quarters since. 227 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Perceptive Advisors held 4,373,974 shares of Edgewise Therapeutics worth $178M as of Q2 2026.
  • Perceptive Advisors sold 50,000 Edgewise Therapeutics shares in Q2 2026, an estimated $1.72M.
  • Edgewise Therapeutics made up 2.67% of Perceptive Advisors's portfolio in Q2 2026, its #11 holding.
  • Perceptive Advisors first reported a position in Edgewise Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • 227 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Perceptive Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.